Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

754 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Advancing the PD-L1 CPS test in metastatic TNBC: Insights from pathologists and findings from a nationwide survey.
Fusco N, Ivanova M, Frascarelli C, Criscitiello C, Cerbelli B, Pignataro MG, Pernazza A, Sajjadi E, Venetis K, Cursano G, Pagni F, Di Bella C, Accardo M, Amato M, Amico P, Bartoli C, Bogina G, Bortesi L, Boldorini R, Bruno S, Cabibi D, Caruana P, Dainese E, De Camilli E, Dell'Anna V, Duda L, Emmanuele C, Fanelli GN, Fernandes B, Ferrara G, Gnetti L, Gurrera A, Leone G, Lucci R, Mancini C, Marangi G, Mastropasqua MG, Nibid L, Orrù S, Pastena M, Peresi M, Perracchio L, Santoro A, Vezzosi V, Zambelli C, Zuccalà V, Rizzo A, Costarelli L, Pietribiasi F, Santinelli A, Scatena C, Curigliano G, Guerini-Rocco E, Martini M, Graziano P, Castellano I, d'Amati G. Fusco N, et al. Among authors: curigliano g. Crit Rev Oncol Hematol. 2023 Oct;190:104103. doi: 10.1016/j.critrevonc.2023.104103. Epub 2023 Aug 16. Crit Rev Oncol Hematol. 2023. PMID: 37595344 Review.
Trop-2 as an Actionable Biomarker in Breast Cancer.
Cursano G, Frigo E, Sajjadi E, Ivanova M, Venetis K, Guerini-Rocco E, Criscitiello C, Curigliano G, Fusco N. Cursano G, et al. Among authors: curigliano g. Curr Genomics. 2023 Nov 22;24(3):129-131. doi: 10.2174/1389202924666230726112233. Curr Genomics. 2023. PMID: 38178982 No abstract available.
Tucatinib's journey from clinical development to clinical practice: New horizons for HER2-positive metastatic disease and promising prospects for brain metastatic spread.
Criscitiello C, Corti C, De Laurentiis M, Bianchini G, Pistilli B, Cinieri S, Castellan L, Arpino G, Conte P, Di Meco F, Gennari A, Guarneri V, Visani L, Livi L, Marchetti P, Puglisi F, Viale G, Del Mastro L, De Placido S, Curigliano G. Criscitiello C, et al. Among authors: curigliano g. Cancer Treat Rev. 2023 Nov;120:102618. doi: 10.1016/j.ctrv.2023.102618. Epub 2023 Aug 22. Cancer Treat Rev. 2023. PMID: 37639757 Review.
Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review.
Miglietta F, Fabi A, Generali D, Dieci MV, Arpino G, Bianchini G, Cinieri S, Conte PF, Curigliano G, De Laurentis M, Del Mastro L, De Placido S, Gennari A, Puglisi F, Zambelli A, Perrone F, Guarneri V. Miglietta F, et al. Among authors: curigliano g. Cancer Treat Rev. 2023 Mar;114:102511. doi: 10.1016/j.ctrv.2023.102511. Epub 2023 Jan 6. Cancer Treat Rev. 2023. PMID: 36638600 Free article. Review.
Corrigendum to "Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review" [Cancer Treatm. Rev. 114 (2023) 102511].
Miglietta F, Fabi A, Generali D, Dieci MV, Arpino G, Bianchini G, Cinieri S, Conte PF, Curigliano G, De Laurentiis M, Del Mastro L, De Placido S, Gennari A, Puglisi F, Zambelli A, Perrone F, Guarneri V. Miglietta F, et al. Among authors: curigliano g. Cancer Treat Rev. 2023 Jun;117:102570. doi: 10.1016/j.ctrv.2023.102570. Epub 2023 May 5. Cancer Treat Rev. 2023. PMID: 37150120 Free article. No abstract available.
Multimodal treatment for resectable neuroendocrine carcinoma of the cervix.
Valenza C, Spada F, Multinu F, Benini L, Borghesani M, Algeri L, Rubino M, Pisa E, Gervaso L, Cella CA, Carinelli S, Bruni S, Schivardi G, Curigliano G, Zanagnolo V, Aletti G, Colombo N, Fazio N. Valenza C, et al. Among authors: curigliano g. Endocr Relat Cancer. 2023 Aug 14;30(10):e230112. doi: 10.1530/ERC-23-0112. Print 2023 Oct 1. Endocr Relat Cancer. 2023. PMID: 37428640
Current practice of genomic profiling of patients with advanced solid tumours in Italy: the Italian Register of Actionable Mutations (RATIONAL) study.
Normanno N, De Luca A, Abate RE, Morabito A, Milella M, Tabbò F, Curigliano G, Masini C, Marchetti P, Pruneri G, Guarneri V, Frassineti GL, Fasola G, Adamo V, Daniele B, Berardi R, Feroce F, Maiello E, Pinto C. Normanno N, et al. Among authors: curigliano g. Eur J Cancer. 2023 Jul;187:174-184. doi: 10.1016/j.ejca.2023.03.027. Epub 2023 Mar 30. Eur J Cancer. 2023. PMID: 37167765 Free article.
Do more targets allow more cancer treatments, or not?
Marchetti P, Curigliano G, Calabria S, Piccinni C, Botticelli A, Martini N. Marchetti P, et al. Among authors: curigliano g. Eur J Cancer. 2023 Jul;187:99-104. doi: 10.1016/j.ejca.2023.03.041. Epub 2023 Apr 7. Eur J Cancer. 2023. PMID: 37137204 Free article.
754 results